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24 Abstract and Keywords
25 Background
26 Depression is common among people with inflammatory bowel disease (IBD), though the 
27 causes remain unclear. We conducted a cross-sectional study to investigate the role of 
28 emotional processing biases in contributing to depression among people with IBD.
29 Materials and methods
30 One hundred and twenty outpatients with IBD were recruited and: i) completed 
31 questionnaires to record: age, sex, social support, socioeconomic status, anxiety and 
32 depression (n=104) , ii) underwent assessments of biases in emotional recognition (n=112), 
33 emotional memory and reinforcement learning iii) had recorded from clinical records: type of 
34 IBD, duration of IBD, IBD activity and iv) provided blood for high-sensitivity C-reactive protein 
35 levels (n=99).
36 Key Results
37 Sixty-eight participants had Crohn’s disease and 49 had ulcerative colitis. Of these, 35 had 
38 active disease and 26 had depression. Those with depression were more likely to be female, 
39 lack social support, have active disease, be taking corticosteroids but not TNF-alpha 
40 inhibitors and exhibit less positive emotional recognition bias. On multivariable regression 
41 analysis, depression was associated independently with lack of social support 
42 (unstandardized regression coefficient (B)=-1.40, p=0.02) and increased disease activity 
43 (B=1.29, p=0.03). Causal steps analysis was consistent with less positive emotional 
44 recognition bias partially mediating the effects of disease activity on depression.
45 Conclusions and inferences
46 This is the first study to demonstrate links between disease activity and less positive biases 
47 in emotional recognition that could explain higher rates of depression among people with 
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48 active IBD. Future prospective studies are required to confirm the effects of emotional 
49 processing biases in depression and allow stronger causal inferences to be drawn. 
50
51 Key Words
52 Inflammatory Bowel Disease, Depression, Inflammation, Cognitive functioning, 
53
54 Key points
55  Depression is common in people with inflammatory bowel disease (IBD), but the 
56 actual causes of depression in this group are unknown
57  We found that depression was independently associated with increased IBD activity, 
58 and that less positive cognitive bias part-mediated the effects of disease activity on 
59 depression
60  This is the first study to demonstrate links between disease activity and less positive 
61 biases in emotional recognition that could explain higher rates of depression among 
62 people with active IBD.
63
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64 Depression affects 14 - 27% patients with inflammatory bowel disease (IBD), which is 
65 approximately 2 to 3 times the prevalence in people without IBD1–3. Depression in IBD is 
66 important because it is associated with more gastrointestinal symptoms independent of 
67 disease severity4, worse health-related quality of life5–8, increased healthcare utilisation9–11, 
68 and possibly relapses in disease activity12–16. Depression is associated with a number of 
69 sociodemographic, clinical and psychological factors1,13,17–21, though many of these risk 
70 factors are inter-related, and the main causes of depression among people with IBD remain 
71 unclear.
72 Recently, there has been considerable interest in the role of inflammation in depression. 
73 Observational studies in healthy and clinical populations have shown that inflammation is 
74 associated with depression22–24. Also, controlled, experimental studies in healthy individuals 
75 have shown that acute inflammation causes short term increases in depressive 
76 symptoms25,26. Among people with severe Crohn’s disease, treatment with the anti-TNF-
77 alpha drugs infliximab and adalimumab has been associated with a rapid reduction in 
78 depression, not attributable solely to reductions in clinical disease activity27–29. However, it is 
79 unclear how inflammation causes depression. We postulate here that the effects of 
80 inflammation may be mediated via negative cognitive biases, particularly biases in the 
81 processing of emotionally salient information (henceforth emotional processing)30. Such 
82 negative cognitive biases are considered central to the development of depression, though 
83 their association with chronic inflammation in people with IBD has not been investigated 
84 previously31,32.
85 We conducted a cross-sectional study among hospital outpatients with IBD to identify 
86 sociodemographic, IBD-related and psychological factors that were independently 
87 associated with depression, and to explore whether negative biases in emotional processing 
88 mediated links between IBD activity and depression.
89 We tested the following hypotheses among outpatients with IBD:
Page 4 of 41Neurogastroenterology and Motility
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Wilkinson
5
90 i) Depression would be independently predicted by socio-demographic characteristics 
91 (age, sex, socioeconomic status, social support), medical characteristics (type of 
92 IBD, IBD activity), and psychological characteristics (negative biases in emotional 
93 processing)
94 ii) Negative biases in emotional processing would mediate the effects of disease activity 
95 on depression
96
97
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98 Materials and methods
99 Subjects
100 We recruited adults with known IBD attending the gastroenterology outpatients and biologic 
101 infusion clinics at the Royal Devon and Exeter hospital between January and June 2017. 
102 Participants were excluded if they were too physically unwell, if they suffered from severe 
103 mental disorder, including severe depression, significant suicidal risk or active psychosis.
104 Sample size calculation
105 Making the a priori assumption that key variables of interest would be normally distributed, 
106 we calculated that a sample of 85 subjects would provide ≥80% power to detect bivariate 
107 correlations of at least r=0.3 between measures of emotional processing, markers of disease 
108 severity and depression at the 5% level of significance (2-sided). Also, we expected this 
109 number of subjects would be provide sufficient power to conduct multivariable regression 
110 analyses using up to 8 independent variables, based on the rule-of-thumb of 10 participant 
111 per independent variable added33.
112 Baseline assessments
113 Data were obtained using a combination of self-report questionnaires, computerized 
114 assessment and by extraction of relevant clinical information from medical records. 
115 Questionnaire assessments
116 A purpose-designed questionnaire was used to record sociodemographic characteristics 
117 including: age, sex, relationship status (categorized as “In relationship” versus “Other”), 
118 educational status (years of education) and employment status (categorized as “In 
119 employment” versus “Other”), smoking status (current smoker, ex-smoker, never smoked) 
120 and previous treatments for depression.
121 We used the following validated questionnaire assessments: 
122 The frequency of depressive symptoms in the previous 2 weeks was assessed using 9-item 
123 Patient Health Questionnaire, PHQ-934. Scores could range from 0 to 27, with higher scores 
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124 indicating worse depression. A cut-off score of ≥10 indicates moderate depressive 
125 symptoms and we used this cut-off to identify cases of depression among our participants.
126 Anxiety was measured using the 7-item General Anxiety Disorder Assessment, GAD-735, 
127 perceived social support was assessed using the seven item ENRICHD social support 
128 inventory36–38 and recent life stresses were assessed using the 12-item List of Threatening 
129 Experiences questionnaire39. The EQ-5D questionnaire was used to assess generic health-
130 related quality of life40 and the 10-item, Short Inflammatory Bowel Disease questionnaire 
131 was used to record disease-specific health-related quality of life41,42. 
132 Questionnaire assessments were completed in clinic following recruitment, though 
133 participants could take them home to complete, if preferred.
134 Data extracted from medical records
135 We recorded demographic data, smoking status, age at diagnosis, disease duration, 
136 Montreal Classification43, prior medical and drug history and previous IBD. Patients 
137 postcodes were used to identify the degree of social deprivation, as determined using the 
138 Index of Multiple Deprivation44. 
139 IBD activity at the time of recruitment was categorized as active versus inactive via 
140 retrospective inspection of medical records. Two experienced clinicians (JG, NH) 
141 independently reviewed clinical and laboratory information for each participant at the time of 
142 recruitment to the study, blind to the outcomes of any research assessments. 
143 Disagreements in ratings were resolved though consensus, with referral to a third 
144 independent clinician (NAK) if agreement could not be reached.
145 Computerized assessment of emotional processing
146 We selected specific tests from a validated computerized neuropsychological test battery 
147 (EMOTICOM)45 to assess performance on emotional perception, emotional memory and 
148 reinforcement learning, which we recently showed were aspects of social and emotional 
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149 processing most likely to be influenced by inflammation30. All tasks were presented on a 
150 Hewlett Packard 755 laptop computer with 15.6” touchscreen.  
151 Emotional recognition task
152 The Emotional Recognition Task (ERT) assessed an individual’s ability to recognize basic 
153 emotions (happy, sad, angry and fearful) from 80 images of people’s eyes (20 of each 
154 emotion), with 10 levels of intensity for each emotion. In each trial a fixation cross was 
155 presented in the center of the screen (random duration between 1500 to 2500 milliseconds), 
156 followed by an image of eyes (250 milliseconds). The image was immediately replaced by a 
157 grey mask (150 milliseconds), following which the participant made a forced choice from four 
158 emotions (happy, sad, angry or fearful). There were in addition 16 filler trials in which 
159 participants were asked to select the age of the eyes in the image (child, young adult, 
160 middle-aged adult and older adult). Performance on the emotional recognition task is 
161 reported as “emotional recognition bias”, calculated as the percentage accuracy for 
162 recognition of happy expressions minus the percentage accuracy for recognition of sad 
163 expressions.
164 Emotional memory recognition task
165 The Emotional Memory Recognition Task (EMRT) was presented in two parts. During the 
166 first phase (encoding) participants were shown 30 photographic scenes without people (10 
167 positive, 10 negative and 10 neutral). In each trial a fixation cross was displayed in the 
168 centre of the screen for 1000 milliseconds, followed by an image also displayed for 1000 
169 milliseconds. Participants were asked to make ratings of valence (1=negative, 9=positive) 
170 and intensity (1=not at all, 9=extremely) for each image. In the second phase (retrieval) 
171 conducted 30 minutes later, participants were shown 30 images from the encoding phase, 
172 each paired with new photographs, which were mirror images of those seen during 
173 encoding. Participants were asked to identify the image seen during encoding. Performance 
174 on the emotional memory task is reported as “emotional memory bias”, calculated as the 
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175 percentage accuracy recall of positive scenes minus the percentage accuracy for recall of 
176 negative scenes.
177 Reinforcement learning 
178 The Reinforcement Learning Task (RLT) assessed speed of learning of visual patterns 
179 associated with reward (winning points) and punishment (losing points). Participants were 
180 shown pairs of colored circles and were instructed to select one of the circles which they 
181 thought would be most likely to win money. Participants were expected to learn through 
182 sampling the circles which of the two circles was most likely to deliver a win, with 
183 probabilities set at 70/30%, unknown to participants. Feedback was given after each 
184 selection and a cumulative tally was displayed. The task was presented in two parts. First, 
185 there were 120 trials in the learning phase. In each trial a fixation cross was presented 
186 (random duration between 500 to 1500 milliseconds) followed by 1 of 4 possible pairs of 
187 colored circles. The circles remained until the participant selected one circle, after which 
188 feedback was displayed for 1000 milliseconds. There were two conditions: reward (2 pairs / 
189 60 trials) or punishment (2 pairs / 60 trials). In the reward condition feedback consists of a 
190 win (win 50p) or failure to win (win 0p), and in the punishment condition feedback consists of 
191 a loss (lose 50p) or avoidance of loss (lose 0p). Next, in the transfer phase there were 48 
192 trials where all possible pairs of circles were presented. Participants were instructed to 
193 continue to select their preferred circle, although no feedback was provided in this phase.
194 Performance on the RLT is reported using learning rate (i.e. how fast the participant learned 
195 new information related with winning and losing, where high scores show that learning was 
196 more rapid), calculated from the learning phase only (not the transfer phase) and the 
197 performance temperature (a measure of the randomness in responding). On initial inspection 
198 of the learning data, it became clear that some subjects were performing no better than 
199 chance (i.e. there was no evidence of learning, with performance on the task at or below 
200 50% correct), which resulted in poor model fit. Once we had excluded these non-performers, 
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201 the model that accounted best for the participant’s performance was the reinforcement 
202 learning model with separate parameters for rewards and losses. Thus, results for 
203 reinforcement learning data presented below are limited to individuals showing evidence of 
204 learning on the task.
205 Blood samples
206 Blood was collected in 7.5 mL EDTA tubes and centrifuged at 2500 g for 10 minutes at 4 C 
207 in a Thermo Scientific Heraeus 16R Megafuge. Within 30 minutes of venipuncture the 
208 separated plasma was divided into 3 aliquots (minimum 0.5 mL per aliquot) and then frozen 
209 at -80 °C for subsequent assay for C-reactive protein (high sensitivity assay, hs-CRP). 
210 Hs-CRP assay
211 Hs-CRP levels were established using Cardiac C-reactive protein (latex) high sensitive, 
212 particle enhanced immunoturbidimetric assay on the 702 module of a Roche / Hitachi cobas 
213 8000 automated analyzer. The lower detection limit for hs-CRP using this system was 0.15 
214 mg/L. One subject had levels below this lower limit of detection (<0.15 mg/L) and, for the 
215 purposes of analysis hs-CRP as a continuous variable, levels for this individual were 
216 assumed to equal 0.15mg/L. In addition, hs-CRP levels were also divided into low and high 
217 hs-CRP categories (≤3 mg/L and >3 mg/L, respectively).
218 Statistical considerations
219 Preliminary examination of the continuous variables using 1-sample Kolmogorov-Smirnov 
220 tests revealed that our a priori assumption that key variables would be normally distributed 
221 was incorrect. In fact, the vast majority of variables were non-parametrically distributed. 
222 Standard transformations did not increase normality, so non-parametric statistical techniques 
223 were used throughout. Socio-demographic, IBD and psychological characteristics are 
224 summarized using median and interquartile range, or number and percentages, as 
225 appropriate. Differences in sociodemographic, IBD and psychological variables according to 
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226 depression status were examined using the Mann Whitney U test for continuous data. Chi-
227 square tests were used to compare categorical data, with Fisher’s Exact test used where 
228 contingency tables included cells with expected frequencies <5. 
229 To identify variables independently associated with depression, multivariable logistic 
230 regression analysis was conducted that included the following independent variables: Block 
231 1: age, sex, socioeconomic status, social support, Block 2: IBD type (Crohn’s Disease, 
232 Ulcerative Colitis, Unclassified) and IBD activity (Active vs Inactive IBD), Block 3: 
233 psychological characteristics (bias in emotional processing). Due to the highly non-
234 parametric distribution of independent variables, for the purposes of the regression analyses 
235 continuous independent variables were converted to binary categories, using a median split 
236 unless other established cut-offs were more appropriate (i.e. PHQ-9≥10  and hs-CRP >3 
237 mg/L).
238 We explored the role of emotional recognition bias as a potential mediator of the association 
239 of disease activity with depression using a causal steps approach, based the methods of 
240 Baron & Kenny46. A series of 3 logistic regression analyses were conducted: 1) Depression 
241 regressed on disease activity, 2) Emotional recognition bias regressed on disease activity, 
242 and 3) Depression regressed on both disease activity and emotional recognition bias, in the 
243 same model. Mediation was considered to have occurred if all of the following conditions 
244 were met (see Figure 1 for illustration): 
245 i. Disease activity predicted depression (the total, unadjusted, effect of predictor on 
246 outcome, path c’).
247 ii. Disease activity predicted emotional recognition bias (the direct effect of predictor 
248 on mediator, path a).
249 iii. Emotional recognition bias significantly predicted depression in a model that also 
250 included disease activity (path b, the direct effect of mediator on outcome).
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251 iv. The regression coefficient of disease activity on depression in the model that also 
252 included emotional recognition bias (path c, the direct effect of predictor on 
253 outcome) was smaller than the coefficient of the total effect (path c’). 
254 If the causal steps approach indicated findings consistent with mediation, a bootstrapping 
255 method with 5000 samples and bias corrected confidence intervals was used to determine 
256 significance of the mediated effect47.
257 Ethical statement
258 All participants provided full informed consent. Full ethical permission was granted by South 
259 West – Cornwall and Plymouth research ethics committee, reference: 16/SW/0209. 
260
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261 Results
262 Participant characteristics
263 One hundred and twenty patient participants agreed to participate in the study. Sixty-eight 
264 patients (57%) had Crohn’s disease, 49 (41%) had ulcerative colitis and the remaining 3 
265 (2%) had IBD unclassified. The median duration of IBD was 9.2 years (IQR 4.2-15.2), with 
266 the median age of onset being 29.9 years (IQR 22.3-43.6). Forty-six patients (38%) were 
267 taking anti-TNF drugs to control their IBD. Full baseline characteristics of study participants 
268 can be seen in Table 1.
269 Of the 120 patients recruited, 35 (29%) were classified as having active IBD. Those with 
270 active disease had higher hs-CRP levels (median levels 5.0 mg/L [IQR 2.75-9.38] vs 1.2 
271 mg/L [IQR 0.50-2.70], Mann Whitney, p<0.0005) and higher white cell counts (median 8.4 × 
272 109/L [IQR 6.80-9.80] vs 6.6 × 109/L [IQR 5.55-7.80], Mann Whitney, p <0.0005). 
273 Furthermore, those with active disease were more likely to be taking corticosteroids (20% vs 
274 1.2%, p=0.001) and less likely to be taking anti-TNF drugs (20% vs 45.9%, p=0.008). 
275 Participants with active disease had worse generic and disease specific health-related 
276 quality of life (EQ-5D index value and VAS; SIBDQ Systemic, Social, Bowel and Emotional 
277 domains of the Short IBD questionnaire, all p’s ≤ 0.005).
278 Overall participants showed a positive bias in emotion recognition [median emotional 
279 recognition bias = +15% (IQR 0.0 – 30.0)] and a negative bias in emotional memory [median 
280 emotional memory bias = -10% (IQR = -30.0 – 0.0)]. Emotional recognition bias was less 
281 positive in people with active disease [median recognition bias +5% (IQR -5.0 – 20.0) vs 
282 +15% (IQR 2.50 – 35.0), Mann Whitney, p=0.028], but was not significantly associated with 
283 hs-CRP (Spearman’s correlation coefficient (ρ) = -0.04, n=101, p = 0.73) or white cell count 
284 (ρ = -0.01, n=112 ,p =0.91). Emotional memory bias and learning rate (win or loss) were not 
285 significantly associated with disease activity or markers of inflammatory activity.
286 Sociodemographic, IBD and psychological factors associated with depression
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287 Of the 120 participants recruited, 105 returned questionnaires, of which 104 included 
288 completed depression assessments. There were no significant differences with regards to 
289 age, sex, socioeconomic status or disease activity between those 104 returning the 
290 depression assessment and the 16 who did not. 
291 Twenty-six participants (25%) were depressed (PHQ-9 score ≥10). Sociodemographic, 
292 clinical and psychological factors that showed univariate associations with depression can 
293 be seen in Table 2. Of note, those with depression were significantly more likely to be 
294 female, lack social support, have active IBD, not be taking anti-TNF alpha inhibitors, have 
295 worse quality of life and exhibit less positive bias on the emotional recognition task [median 
296 emotional recognition bias = +2.5 (IQR -25.0 – 15.0) in depressed vs +15% (0.0 – 35.0) in 
297 the non-depressed, Mann-Whitney, p=0.002]. Depression was not associated with laboratory 
298 markers of inflammatory activity (hs-CRP or white cell count), emotional memory, 
299 reinforcement learning related to reward or loss.
300 Using multivariable logistic regression, the overall model was significant (Chi-square = 24.9, 
301 p=0.001, Cox and Snell R-square = 0.22). Within the model, depression was independently 
302 associated with less social support [odds ratio (OR) = 0.25 (95% CI = 0.08 – 0.76), p=0.02] 
303 and greater disease activity [OR = 3.6 (95% CI = 1.14 – 11.60) p=0.03) (Table 3). Age, sex, 
304 Index of Multiple Deprivation and emotional recognition bias [OR  = 0.39, (95% CI = 0.12 – 
305 1.27), p=0.12] did not make any significant independent contribution to the full regression 
306 model. 
307 Since disease activity and emotional recognition bias showed a significant univariate 
308 association with each other, we explored the effect of removing disease activity from the 
309 regression model. When disease activity was removed from the model, the overall model 
310 remained significant (Chi-square = 20.1, p=0.003, Cox and Snell R-square = 0.182), and 
311 less positive emotional recognition bias (B=-1.20, SE=0.58, p=0.04, Exp (B) = 0.30) and less 
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312 social support (B=-1.31, SE=0.55, p=0.02, Exp (B) = 0.27) were the only variables to make a 
313 significant independent contribution to the model. 
314 Using the causal steps approach, disease activity was associated with emotional recognition 
315 bias (B= -0.93, p=0.043) and both disease activity (B = 1.47, p=0.003) and emotional 
316 recognition bias (B=-1.27, p=0.019) predicted depression. The contribution of disease 
317 activity to the model decreased when emotional recognition was added to the model 
318 (B=1.29, p=0.012, Figure 2), consistent with emotional recognition partially mediating the 
319 effects of disease activity on depression (Figures 1b). Bootstrap test of indirect effect was 
320 significant, and proportion of total effect mediated = 19.8%. Disease activity was also 
321 associated with anxiety (B=1.2, p=0.03), though emotional recognition bias did not meet 
322 criteria for mediation in this association, since the association between emotional recognition 
323 bias and anxiety was non-significant (B=-0.48, p=0.38).
Page 15 of 41 Neurogastroenterology and Motility
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Wilkinson
16
324 Discussion
325 We found that depression affected 25% of people with IBD and was associated with a wide 
326 range of sociodemographic, IBD-related and psychological factors including less positive 
327 biases in emotional recognition. However, on multivariable analysis, depression was 
328 predicted by a lack of social support and greater IBD activity, only. Causal steps analysis 
329 suggested that emotional recognition bias partially mediated the relationship between 
330 disease activity and depression, as we hypothesized.
331 This is the first study to explore links between disease activity and emotional processing 
332 biases, with the aim of understanding mechanisms underpinning the development of 
333 depression among people with IBD. Strengths of our study include the recruitment of a 
334 representative sample of outpatients with IBD and the use of standardized assessments to 
335 record key variables of interest, so we are confident that our findings are generalizable, valid 
336 and reliable. Finally, our measures of emotional processing were selected from a battery of 
337 tests designed specifically to evaluate changes in emotional processing associated with 
338 mental disorders, informed by a systematic review of experimental findings relating to acute 
339 inflammation. 
340 The main weakness of our study was its cross-sectional design, meaning that we could not 
341 determine the direction of causation of any of the observed associations. Despite our causal 
342 steps approach, we recognize that mediation analyses based on cross-sectional data must 
343 be regarded as preliminary, since spurious and inflated associations may occur48. Also, , 
344 since conventional symptom scores are heavily weighted by quality of life and well-being 
345 domains that can be influenced directly by depression, use of such scores to assess IBD 
346 activity risks inflating the apparent association between IBD activity and depression. To 
347 avoid this, we used the opinions of expert gastroenterologists to determine clinical disease 
348 activity via retrospective inspection of medical records, blinded to depression status and the 
349 outcomes of research assessments. Whilst the fact that people whose IBD was classified as 
350 active had significantly higher hs-CRP levels and worse health-related quality of life scores, , 
Page 16 of 41Neurogastroenterology and Motility
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Wilkinson
17
351 provides some confirmation of the validity of our IBD activity assessment method, we 
352 acknowledge that such an assessment is fundamentally subjective and therefore vulnerable 
353 to bias.Future studies should consider using more valid and reliable measures of IBD activity 
354 such as fecal calprotectin.
355 We interpret our findings as confirming that depression is common in hospital outpatients 
356 with IBD, and that having active IBD and lacking of social support were the strongest 
357 predictors of depression. This finding is consistent with our research in rheumatoid arthritis, 
358 which showed that depression was more likely among people who experienced life 
359 difficulties in both disease-related and non-disease related domains49. Due to our small 
360 population size and the loss of statistical power due to shifting from the planned multivariable 
361 linear regression to logistic regression to accommodate the non-parametric distribution of 
362 our key variables, we cannot conclud  that other factors are unimportant in contributing to 
363 depression at an individual level, merely that disease activity and social support were 
364 important predictors of depression among our participants. 
365 Whilst depression was associated with clinical disease activity, we did not find that 
366 depression was associated with hs- C-reactive protein. This would seem to contradict the 
367 ever growing observational evidence that depression is associated with inflammation. One 
368 explanation could be that most patients recruited to this study were taking drugs that are 
369 recognized to reduce inflammation, such as corticosteroids and TNF-alpha inhibitors, which 
370 could have moderated the association between inflammation and depression50–52. Common 
371 use of such powerful anti-inflammatory drugs in clinical populations could mean that findings 
372 from research into acute inflammation in healthy individuals performed in laboratory settings 
373 or using population based, observational studies cannot necessarily be extrapolated directly 
374 to clinical populations receiving such treatments. Another explanation could be that we did 
375 not measure mediators of inflammation sufficiently thoroughly, being limited to CRP, an 
376 inactive marker of depression. Furthermore, exclusion of IBD sufferers with most severe 
377 depression and most severe IBD may have weakened associations that would have 
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378 otherwise been apparent if people with more severe health problems had been included. 
379 Finally, of course, this lack of association could indicate that there is no association between 
380 inflammation and depression among people with IBD.
381 Our finding of a reduction of positive bias during emotional recognition in people with active 
382 compared to inactive IBD was robust and consistent with the previous small fMRI study of 
383 patients with ulcerative colitis53. Our findings that less positive biases in emotional 
384 recognition partially mediate the association between IBD activity and depression are new 
385 and start to elucidate the mechanisms underpinning depression among people with IBD, and 
386 possibly other long term conditions. 
387 Further research is required to investigate mechanisms underlying the development and 
388 maintenance of depression and, in particular, to test our hypotheses that that the association 
389 between disease activity / inflammation and depression might be mediated via emotional 
390 processing biases. Larger participant numbers will increase statistical power so possibly 
391 identifying other factors that are associated with depression but also facilitate analysis on 
392 subgroups not taking anti-inflammatory drugs, which may influence the associations 
393 between depression and disease activity. Study of populations with other chronic 
394 inflammatory conditions may reveal subtle differences in the effects of inflammation and anti-
395 inflammatory drugs on depression. Assessment of cytokines and a broader range of 
396 cognitive processes may provide a more comprehensive investigation of mechanisms 
397 underlying depression. Prospective study design will enable stronger causal inferences to be 
398 drawn if the nature of the temporal relationships between presumed predictors and 
399 dependent variables can be established. Emotional recognition biases did not mediate the 
400 association between disease activity and anxiety in this preliminary study, though anxiety 
401 should be considered alongside depression in future studies of the impact of inflammation. 
402 Our findings raise the possibility that psychological interventions targeting emotional 
403 recognition biases among people with IBD, could be used to treat or even prevent 
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404 depression in high risk individuals, such as those with active IBD, and thereby possibly 
405 improve medical as well as psychological outcomes. 
406
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606 Tables
607 Table 1 Characteristics of subjects recruited (Median (IQR) or n (%))
Subject characteristic
Socio-demographic 
characteristics
Age Years 44.0 (33.3-56.0)
Sex Male 52 (43.3)
Ethnicity White British 120 (100)
Socio-economic IMD decile 6.0 (4.0-8.0)
Education (n=98) Years 15.0 (12.0-18.0)
Employment Working 68 (64.8)
Smoking Curr nt
Ex
Never
10 (8.3)
21 (17.5)
89 (82.5)
Relationships In a relationship 73 (69.5)
Lives alone 14 (13.3)
ENRICHD (n=105) 26.0 (22.0-29.0)
IBD characteristics
Disease type Crohn’s
UC
IBD-U
68 (56.7)
49 (40.8)
3 (2.5)
Disease duration Years 9.2 (4.2-15.2)
Age at diagnosis Years 29.9 (22.3-43.6)
Disease activity Active disease 35 (29.2)
Crohn’s Disease Montreal
Classification (n=68)
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Subject characteristic
Age A1: Age <17
A2: 17-40
A3: >40
9 (13.2)
42 (61.8)
17 (25.0)
Location of Crohn’s L1: Ileal
L2: Colonic
L3: Ileocolonic 
+ L4: Upper GI
28 (41.2)
17 (25.0)
23 (33.8)
12 (17.6)
Crohn’s behaviour B1: Inflammatory
B2: Stricturing
B3: Penetrating
+ p: Perianal
41 (60.3)
21 (30.9)
6 (8.8)
10 (14.7)
UC Montreal Classification E1: Proctitis
E2: Distal colitis
E3: Total colitis
8 (15.4)
20 (38.5)
24 (46.2)
Medications 5 ASA 
Corticosteroids
Thiopurine
Methotrexate
Anti-TNF 
Vedolizumab
Ustekinumab
32.26.7
8 (6.7)
46 (38.3)
4 (3.3)
46 (38.3)
22 (18.3)
2 (1.7)
Prior surgeries None
Ileocecal resection
Subtotal colectomy
Small bowel resection
Right hemicolectomy
94 (78.3)
20 (16.7)
3 (2.5)
2 (1.7)
1 (0.8)
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Subject characteristic
Baseline laboratory indices Haemoglobin (g/L) 134.0 (124.0-141.8)
MCV (fL) 89.3 (85.6-94.0)
White cell count (x109/L) 6.9 (5.8-8.6)
Baseline laboratory indices Platelet count (x109/L) 242.0 (212.3-304.8)
Haematocrit (vol%) 39 (37-41)
Hs-CRP (n=107 mg/L) 1.7 (0.80-4.70)
Hs C-reactive protein >3 
mg/L (n=107)
40 (37.4)
SIBDQ subscales Systemic (n=105)
Social (n=104)
Bowel (n=104)
Emotional (n=104)
4.5 (3.3-5.5)
6.0 (5.0-7.0)
5.3 (4.3-6.0)
5.0 (3.7-6.0)
Total SIBDQ (n=105) 4.9 (4.3-5.8)
EQ-5D VAS (n=105) 75.0 (62.5-85.0)
EQ-5D index value (n=105) 0.70 (0.72-0.95)
Psychological 
characteristics
PHQ-9 (n=104) 5.5 (3.0-10.5)
PHQ-9>=10 (n=104) 26 (25.0)
GAD-7 (n=105) 5.0 (1.0 – 8.0)
GAD-7>=10 (n=105) 18 (17.1)
Recent Life stresses Yes 60 (57.1)
Cognitive assessments
Emotional recognition bias 
(n=112)
15.0 (0.0-30.0)
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Subject characteristic
Emotional memory bias 
(n=108)
-10 (-30 – 0.0)
Reward and punishment 
processing
Learning rate Win (n=48*)
Temperature Win (n=48) 
Learning rate Loss (n=48*)
Temperature loss (n=48)
0.10 (0.02-0.56)
0.17 (0.03-0.46)
0.22 (0.06-0.53)
1.0 (0.72-1.08)
608
609 Number of participants (n) = 120, unless otherwise stated; IMD = Index of multiple 
610 deprivation; SIBDQ = Short Inflammatory Bowel Disease questionnaire 
611 IQR=interquartile range
612 *Individuals showing no evidence of learning were excluded from these results
Page 32 of 41Neurogastroenterology and Motility
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Wilkinson
33
Table 2 Comparing depressed with non-depressed 
Characteristic Depressed
(N=26)
Non-depressed
(N=78)
Comparison
Socio-demographic factors
Age Years 42.5(33.8-50.8) 49.5(35.0-59.0) MW, p=0.09
Sex Male 7 (26.9) 40 (51.3)  2(1)=4.7, p=0.031𝜒
Ethnicity White British 26 (100) 78 (100)
Socio-economic IMD decile 5.0(4.0-8.0) 6.0(4.0-8.0) MW, p=0.45
Education Years 13(12.5-18.0) 15(12.0-17.8) MW, p=0.83
Employment Working 13 (50) 54 (69.2)  2(1)=3.1, p=0.08𝜒
Smoking Current
Ex
Never
3 (11.5)
7 (26.9)
16 (61.5)
3 (3.8)
13 (16.7)
62 (79.5)
 2(2)= 3.9, p=0.14𝜒
Relationships In a relationship 16 (61.5) 56 (71.8)  2(1)=0.96, p=0.33𝜒
Lives alone 3 (11.5) 11 (14.1) FET, p=1.0
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Characteristic Depressed
(N=26)
Non-depressed
(N=78)
Comparison
ENRICHD 21.0(15.8-23.3) 27.5(24.0-29.3) MW, p<0.0005
IBD characteristics
Disease type Crohn’s
UC
IBD-U
15 (57.7)
10 (38.5)
1 (3.8)
40 (51.3)
37 (47.4)
1 (1.3)
 2(2)=1.17, p=0.56𝜒
Disease duration Years 5.9(1.0-14.7) 10.1(4.3-16.0) MW, p=0.054
Age at diagnosis Years 29.6(20.9-47.0) 33.0(24.3-47.6) MW, p=0.45
Disease activity Active disease 13 (50) 17 (21.8)  2(1)=7.4, p=0.007𝜒
A1: Age <17
A2: 17-40
A3: >40
2 (13.3)
8 (53.3)
5 (33.3)
4 (10.0)
24 (60.0)
12 (30.0)
 2(2)=0.23, p=0.89𝜒
L1: Ileal
L2: Colonic
L3: Ileocolonic 
7 (46.7)
3 (20.0)
5 (33.3)
13 (32.5)
12 (30.0)
15 (37.5)
 2(2)=1.05, p=0.59𝜒
Crohn’s Disease 
Montreal
Classification
+ L4: Upper GI 5 (33.3) 4 (10.0) FET, p=0.095
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Characteristic Depressed
(N=26)
Non-depressed
(N=78)
Comparison
B1: Inflammatory
B2: Stricturing
B3: Penetrating
9 (60.0)
5 (33.3)
1 (6.7)
24 (60.0)
12 (30.0)
4 (10.0)
 2(2)=0.17, p=0.92𝜒
+ p: Perianal 2 (13.3) 6 (15.0)  2(1)=0.02, p=1.0𝜒
UC Montreal 
Classification
E1: Proctitis
E2: Distal colitis
E3: Total colitis
4 (36.4)
3 (27.3)
4 (36.4)
4 (10.5)
17 (44.7)
17 (44.7)
 2(2)=4.27, p=0.12𝜒
Medications 5 ASA 
Corticosteroids
Thiopurine
Methotrexate
Anti-TNF 
Vedolizumab
Ustekinumab
9 (34.6)
3 (11.5)
7 (26.9)
1 (3.8)
3 (11.5)
6 (23.1)
1 (3.8)
22 (28.2)
4 (5.1)
32 (41.0)
3 (3.8)
33 (42.3)
13 (16.7)
1 (1.3)
 2(1)=0.38, p=0.54𝜒
FET, p=0.36
 2(1)=1.66, p=0.20𝜒
FET, p=1.0
 2(1)=8.2, p=0.004𝜒
FET, p=0.56
FET, p=0.44
Prior surgeries None 20 (76.9) 64 (82.1)  2(4)=2.9, p=0.57𝜒
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Characteristic Depressed
(N=26)
Non-depressed
(N=78)
Comparison
Ileocecal resection
Subtotal colectomy
Small bowel resection
Right hemicolectomy
5 (19.2)
0 (0.0)
1 (3.8)
0 (0.0)
9 (11.5)
3 (3.8)
1 (1.3)
1 (1.3)
Haemoglobin (g/L) 130.5(117.8-143.0) 134.5(127.8-143.5) MW, p=0.18
MCV (fL) 88.7(84.0-93.0) 89.3(85.7-94.2) MW, p=0.53
White cell count (x109/L) 7.4(6.0-9.2) 6.7(5.7-8.2) MW, p=0.24
Platelet count (x109/L) 253.5(220.0-355.0) 234.0(207.5-299.3) MW, p=0.07
Haematocrit (vol%) 0.38(0.33-0.41) 0.40(0.37-0.42) MW, p=0.13
Baseline 
laboratory indices 
Hs-C-reactive protein > 
3mg/L (n=99)
9 (39.1) 23 (31.1)  2(1)=5.1, p=0.473𝜒
SIBDQ subscales Systemic
Social
Bowel
Emotional
3.5(2.4-4.1)
5.0(3.5-5.6)
4.3(3.5-5.3)
3.3(2.9-3.7)
4.5(3.5-5.5)
6.5(5.0-7.0)
5.7(4.7-6.3)
5.3(4.3-6.3)
MW, p<0.0005
MW, p<0.0005
MW, p<0.0005
MW, p<0.0005
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Characteristic Depressed
(N=26)
Non-depressed
(N=78)
Comparison
Total SIBDQ 4.0(3.3-4.6) 5.4(4.6-6.1) MW, p<0.0005
EQ-5D VAS 62.5(43.8-70.0) 80.0(70.0-85.3) MW, p<0.0005
EQ-5D index 
value
0.72(0.53-0.76) 0.88(0.74-1.00) MW, p<0.0005
Psychological characteristics
PHQ-9 13.0(12.0-16.0) 5.0(2.0-6.3) MW, p<0.0005
GAD-7 9.0 (6.0 – 12.0) 2.0 (0.0-5.250 MW, p<0.0005
Recent Life 
stresses 
Yes 22 (84.6) 37 (47.4)  2(1)=11.0, p=0.001𝜒
Cognitive assessments
Emotional recognition 2.5(-25.0-15.0) 15.0(0.0-35.0) MW, p=0.002
Emotional memory -10.0(-30.0-0.0) -20.0(-30.0-0.0) MW, p=0.72
Reward and punishment processing
- Learning rate Win (n=43*)
- Temperature Win (n=43*)
0.05 (0.03-0.21)
0.14 (0.03-0.36)
0.12 (0.02-0.56)
0.19 (0.02-0.48)
MW, p=0.69
MW, p=0.71
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Characteristic Depressed
(N=26)
Non-depressed
(N=78)
Comparison
- Learning rate Loss (n=43*)
- Temperature Loss (n=43*)
0.30 (0.11-0.64)
0.96 (0.72-1.07)
0.20 (0.02-0.53)
1.0 (0.66-1.08)
MW, p=0.34
MW, p=0.99
Number of participants (n) = 104 (the number completing the depression assessment), unless otherwise stated; 
IMD = Index of multiple deprivation
SIBDQ = Short Inflammatory Bowel Disease questionnaire; IQR=interquartile range; FET = Fisher’s Exact Test (2-sided), used 
when cross-tabulation includes cells with expected count<5
*Individuals showing no evidence of learning were excluded from these results
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Table 3 Multivariable predictors of depression 
O.R. 95% CI Sig.
Age < 45 yrs versus ≥45 yrs 0.71 0.23 - 2.24 0.56
Sex 2.11 0.68 – 6.56 0.20
IMD category (high vs low) 0.82 0.27 – 2.51 0.72
Social support (high versus low) 0.25 0.08 – 0.76 0.02
Type of IBD (Crohn’s versus UC) 1.44 0.54 – 3.88 0.47
Disease activity (Active versus inactive) 3.64 1.14 – 11.60 0.03
Emotional Recognition categorical (more 
positive versus more negative) 
0.39 0.12 – 1.27 0.12
Constant 0.18 0.30
OR = Odds ratio
CI = confidence intervals
IMD = Index of multiple deprivation.
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Figure Legends
Figure 1
C’= total effect of predictor on outcome
a = direct effect of predictor on mediator
b = direct effect of mediator on outcome
c = direct effect of predictor on outcome
a x b = indirect effect of predictor on outcome via mediator
Figure 2
ap≤0.001, bp ≤0.01, cp ≤0.05
Paths annotated with unstandardized regression coefficients
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Figure 1 Method used for testing mediation 
 
Figure 2 Path diagram of mediation 
 
 
ap≤0.001 bp≤0.01 c≤0.05.
Paths annotated with unstandardised regression coefficients.
Disease activity Depression
Emotional 
recognition bias
-0.93c -1.27c
1.47b    (1.29c)
Indirect effect= 0.07 (0.01, 0.18)
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